✓
Open
30 Jul to 1 Aug, 2024
✓
Close
30 Jul to 1 Aug, 2024
3
Allotment
—
✓
Listing
Tue, Aug 6, 2024
Price Band
₹646 to ₹679
Issue Size
2,73,68,143 shares (agg. up to ₹1,857 Cr)
Lot Size
22 Shares
Listing Date
Tue, Aug 6, 2024
Latest GMP
₹43
Est. Gain
6.33%
✦ AI Insight
GMP Trend
06-08-2024₹43Est. ₹722+6.33%
05-08-2024₹43Est. ₹722+6.33%
04-08-2024₹86Est. ₹765+12.67%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 35.54x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Total Income | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| NET Worth | 709.50 | 717.19 | 621.98 |
| Reserves and Surplus | 861.01 | 868.70 | 787.79 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Ltd. | Mainboard | ₹1,952.03 Cr | ₹1008 | 34.55 | ₹1,359.15 | +34.84% | ₹1,925.80 |
| Innova Captab Ltd. | Mainboard | ₹570.00 Cr | ₹448 | 31.64 | ₹541.40 | +20.85% | ₹1,171.80 |
| Blue Jet Healthcare Ltd. | Mainboard | ₹840.27 Cr | ₹346 | 37.49 | ₹413.40 | +19.48% | ₹581.50 |
| Valiant Laboratories Ltd. | Mainboard | ₹152.46 Cr | ₹140 | 15.71 | ₹170.25 | +21.61% | ₹114.13 |
| Concord Biotech Ltd. | Mainboard | ₹1,550.52 Cr | ₹741 | 32.29 | ₹942.80 | +27.23% | ₹1,470.50 |
| Medicamen Organics Ltd. | SME | ₹10.54 Cr | ₹34 | 30.53 | ₹144.70 | +325.59% | ₹26.50 |
| Quest Laboratories Ltd. | SME | ₹43.16 Cr | ₹97 | 23.03 | ₹147.35 | +51.91% | ₹82.00 |
| Zenith Drugs Ltd. | SME | ₹40.68 Cr | ₹79 | 18.4 | ₹105.15 | +33.10% | ₹48.85 |
| Sunrest Lifescience Ltd. | SME | ₹10.85 Cr | ₹84 | 12.33 | ₹79.80 | -5.00% | ₹39.00 |
| Mono Pharmacare Ltd. | SME | ₹14.84 Cr | ₹28 | null | ₹30.45 | +8.75% | ₹9.00 |
| Shelter Pharma Ltd. | SME | ₹16.03 Cr | ₹42 | 5.62 | ₹41.96 | -0.10% | ₹31.00 |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment/prepayment of all or certain borrowings of our Company | 159.91 |
| 2 | Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited | 227.09 |
| 3 | Funding incremental working capital requirements of our Company | 55.00 |
| 4 | Pursuing inorganic growth initiatives through acquisitions | 27.87 |
| 5 | General corporate purposes | 167.50 |
About Akums Drugs IPO
Updated on Aug 12, 2026
Contact Details
Akums Drugs & Pharmaceuticals Ltd. Address304, Mohan PlaceLSC Saraswati ViharDelhi, New Delhi, 110034+91 11 6904 1000cs@akums.netVisit Website